Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 06 Mar 2023
Obesity continues to exist around the world despite the risk to health and death from illness and disease.
Read Full NewsPhase 3b study revealed Itvisma's safety and efficacy in treating spinal muscular atrophy, showing modest motor function improvements in patients previously on other therapies.
FDA Approves Nerandomilast (Jascayd) Tablets for Progressive Pulmonary Fibrosis
Renal Transplantation May Lower Sleep Disorder Risk Versus Dialysis
BMI, Inflammatory Bowel Disease Both Show Causal Effect on HS Development
The HCPFive: Top News for Healthcare Providers from the Week of 12/14
1.
Survival rates for incurable larynx cancer investigated for first time
2.
Oncologist Sued for Double-Billing; Pharmacy Deserts; 'She Loved Scotch and Pizza'
3.
Dr. Prerana S. Nesargi's message for Childhood Cancer Awareness Month 2023 is to increase understanding of pediatric oncology.
4.
A small rise in cancer was observed following the 1986 Chernobyl accident.
5.
One possible target in acute myeloid leukemia is the reductive carboxylation of glutamine.
1.
Understanding Colon Cancer: Symptoms, Causes, and Treatment Options
2.
Improving TIVAP Use: Review of Standardization and Optimization Practices
3.
Chondroma: What it is and How it Affects Your Health
4.
Deciphering FFR: A Comprehensive Guide to Understanding Its Meaning
5.
Navigating the Unknown: How to Cope with Anaplastic Thyroid Cancer
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
2.
Current Scenario of Cancer- Final Discussion on the Importance of Genomic Testing & Advancement in Diagnosis and Treatment
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I
4.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge